Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population

Last updated: June 25, 2025
Sponsor: NYU Langone Health
Overall Status: Active - Recruiting

Phase

N/A

Condition

Kidney Disease

Nephropathy

Kidney Failure

Treatment

Transcutaneous electrical nerve stimulation unit (TENS)

Clinical Study ID

NCT05981183
23-00778
  • Ages 18-80
  • All Genders

Study Summary

The purpose of this pilot interventional study is to collect preliminary data on the application of a transcutaneous auricular vagal nerve stimulation (taVNS) device in patients with chronic kidney disease (CKD). This data will enhance understanding of the short-term safety, tolerability and effects of this novel therapeutic approach in the setting of CKD. The primary aims are to investigate the feasibility of the protocol and generate preliminary signals of efficacy and tolerability for two different doses of vagal nerve stimulation. The pilot estimates will be used to design a larger scale study that may lead to potentially targeted interventions to reduce cardiovascular (CV) mortality in the CKD population.

Eligibility Criteria

Inclusion

Inclusion Criteria:

• Individual 18-80 years of age with CKD stage 3-5 (eGFR <60 mL/min/1.73m2) on most recent outpatient labs.

Exclusion

Exclusion Criteria:

  • Pacemaker dependent

  • Prisoners

  • Pregnant women. A pregnancy test will be offered if a subject is concerned aboutbeing pregnant.

  • Not capable of informed consent

  • Know autonomic function disorder (e.g. Parkinson's disease with autonomicdysfunction)

  • ICD or PPM precluding assessment of heart rate variability (e.g. chronic atrialfibrillation)

  • Recent myocardial infarction (4 weeks or less)

  • Maintenance dialysis

  • Epilepsy

  • Patients on labetalol (labetalol will interfere with catecholamine measurements)

  • Patients with diabetes

  • At least 50% of cohort must not be on beta blockers. This will help to distinguishthe confounding effects of beta blockers.

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: Transcutaneous electrical nerve stimulation unit (TENS)
Phase:
Study Start date:
August 07, 2023
Estimated Completion Date:
January 07, 2026

Connect with a study center

  • NYU Langone Health

    New York, New York 11215
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.